| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 06/11/2009 | US20090148830 Identification of microorganisms causing acute respiratory tract infections (ari) |
| 06/11/2009 | US20090148555 Dihydroxy-Acid Dehydratase Gene and Use Thereof |
| 06/11/2009 | US20090148539 Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 06/11/2009 | US20090148507 Chimeric polypeptides containing chemokine domains |
| 06/11/2009 | US20090148477 Adenoviral vector-based malaria vaccines |
| 06/11/2009 | US20090148471 Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
| 06/11/2009 | US20090148468 Screening blood and identifying immunologically active antigen of herpes simplex virus (HSV) which attacks skin; diagnosing viral infection; viricides |
| 06/11/2009 | US20090148465 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
| 06/11/2009 | US20090148461 Anti fgf23 antibody and a pharmaceutical composition comprising the same |
| 06/11/2009 | US20090148457 Hepatocyte growth factor receptor antagonists and uses thereof |
| 06/11/2009 | US20090148454 Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor |
| 06/11/2009 | US20090148451 Therapeutic anti-cytomegalovirus compounds |
| 06/11/2009 | US20090148449 Antibodies against cd38 for treatment of multiple myeloma |
| 06/11/2009 | US20090148441 Anti-Cancer Antibodies With Reduced Complement Fixation |
| 06/11/2009 | US20090148438 Binding Moieties Based on Shark Ignar Domains |
| 06/11/2009 | US20090148436 Antibody to gdf8 and uses thereof |
| 06/11/2009 | US20090148434 Antibody Compositions and Methods |
| 06/11/2009 | US20090148427 Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof |
| 06/11/2009 | US20090148425 Therapeutic method for blood coagulation disorder |
| 06/11/2009 | US20090148424 Reversibly immortalized mammalian liver cells and use thereof |
| 06/11/2009 | US20090148408 Lactobacilli expressing biologically active polypeptides and uses thereof |
| 06/11/2009 | US20090148405 Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf) receptor ligands |
| 06/11/2009 | US20090148403 Interleukin-9 Antagonist Muteins and Their Pharmacological Methods of Use |
| 06/11/2009 | US20090148383 Anticoagulation Agent and Uses Thereof |
| 06/11/2009 | CA2853475A1 Genes that increase plant oil and method for using the same |
| 06/11/2009 | CA2743701A1 Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
| 06/11/2009 | CA2708532A1 Anti-nr10 antibody and use thereof |
| 06/11/2009 | CA2708322A1 Genes that increase plant oil and method for using the same |
| 06/11/2009 | CA2708321A1 Genes that increase plant oil and method for using the same |
| 06/11/2009 | CA2708037A1 Mutant proteins and methods for producing them |
| 06/11/2009 | CA2707944A1 Methods for generating marker free transgenic plants |
| 06/11/2009 | CA2707919A1 A subunit vaccine for aquaculture |
| 06/11/2009 | CA2707689A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 06/11/2009 | CA2707687A1 Lactate dehydrogenase-expressing cassette, transformant yeast strain and method of producing lactic acid |
| 06/11/2009 | CA2707658A1 Protease variants for pharmaceutical use |
| 06/11/2009 | CA2707603A1 Seed-preferred gene promoters from the castor plant |
| 06/11/2009 | CA2707586A1 Chimeric and proline rich protein promoters for expression in plants |
| 06/11/2009 | CA2707539A1 Rna antagonist compounds for the modulation of pik3ca expression |
| 06/11/2009 | CA2707446A1 Industrial production of organic compounds using recombinant organisms expressing methyl halide transferase |
| 06/11/2009 | CA2707444A1 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 06/11/2009 | CA2707266A1 Recombinantly modified plasmin |
| 06/11/2009 | CA2707201A1 G immunoglobulin used against anthrax toxins |
| 06/11/2009 | CA2706918A1 Lac expression system |
| 06/11/2009 | CA2706894A1 Biological systems for production of commercially valuable compounds |
| 06/11/2009 | CA2706881A1 Tle3 as a marker for chemotherapy |
| 06/11/2009 | CA2706659A1 Hcv ns3 protease replicon shuttle vectors |
| 06/11/2009 | CA2706258A1 Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof |
| 06/11/2009 | CA2706257A1 Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof |
| 06/11/2009 | CA2705461A1 Novel vaccines against multiple subtypes of influenza virus |
| 06/11/2009 | CA2704518A1 Engineering enzymatically susceptible proteins |
| 06/11/2009 | CA2703790A1 Anti-vegf antibodies |
| 06/10/2009 | EP2067868A2 Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| 06/10/2009 | EP2067864A1 Method for producing L-lysine utilizing microorganism |
| 06/10/2009 | EP2067863A2 Methods and compositions for diseases associated with amyloidosis |
| 06/10/2009 | EP2067862A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/10/2009 | EP2067861A1 Animals of the rattus genus wherein msh6 expression is functionally decreased and methods for the generation of specific mutants therefrom |
| 06/10/2009 | EP2067860A1 Method for selection of hop strain, bleeding marker for use in selection of hop strain, and primer set |
| 06/10/2009 | EP2067859A1 Use of activated cytokinin-biosynthesizing enzyme gene |
| 06/10/2009 | EP2067858A1 Animal models for neurodegenerative diseases |
| 06/10/2009 | EP2067857A1 Method for production of dipeptide |
| 06/10/2009 | EP2067854A1 Improved bacterial host cell for the direct expression of peptides |
| 06/10/2009 | EP2067791A1 Prophylactic or therapeutic agent for cancer |
| 06/10/2009 | EP2067790A2 Agonist antibody against protein tyrosine kinase SAL-S1 |
| 06/10/2009 | EP2067789A1 Anti-P selectin antibodies |
| 06/10/2009 | EP2067788A2 Fab fragment libraries and methods for their use |
| 06/10/2009 | EP2067783A1 Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| 06/10/2009 | EP2067488A1 Albumin fusion proteins |
| 06/10/2009 | EP2067487A2 Immunomodulatory formulations and methods for use thereof |
| 06/10/2009 | EP2067472A1 Compositions and methods for the diagnosis and treatment of tumor |
| 06/10/2009 | EP2067402A1 Transponson-mediated mutagenesis in spermatogonial stem cells |
| 06/10/2009 | EP2067031A1 Rapid in vivo model for angiogenesis |
| 06/10/2009 | EP2066817A1 Molecular switches and methods for their use |
| 06/10/2009 | EP2066808A2 Isolated polynucleotides, nucleic acid constructs, methods and kits for localization of rna and/or polypeptides within living cells |
| 06/10/2009 | EP2066795A2 Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening |
| 06/10/2009 | EP2066794A1 Animal model for the selection and validation of agents active against pulmonary emphysema and colorectal cancer |
| 06/10/2009 | EP2066793A1 Transgenic bioluminescent plants |
| 06/10/2009 | EP2066792A1 Nucleic acid purification method using anion exchange |
| 06/10/2009 | EP2066791A2 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| 06/10/2009 | EP2066790A2 Galactosyltransferase |
| 06/10/2009 | EP2066788A2 Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor |
| 06/10/2009 | EP2066781A1 Target genes for strain-specific diagnostic of ehrlichia ruminantium and use thereof |
| 06/10/2009 | EP2066709A1 Particles and their use in a method for isolating nucleic acid or a method for isolating phosphoproteins |
| 06/10/2009 | EP2066690A2 Membrane-anchored 2 microglobulin covalently linked to mhc class i peptide epitopes |
| 06/10/2009 | EP2066686A1 Stabilizing compositions and methods for extraction of ribonucleic acid |
| 06/10/2009 | EP2066428A1 Compositions and devices for electro-filtration of molecules |
| 06/10/2009 | EP2066349A2 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 06/10/2009 | EP2066343A2 Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications |
| 06/10/2009 | EP2066339A2 Compositions and methods of enhancing immune responses |
| 06/10/2009 | EP2066334A1 Rnai methods and compositions for stimulating proliferation of cells with adherent junctions |
| 06/10/2009 | EP1877559A4 Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers |
| 06/10/2009 | EP1874110A4 Plant promoters, terminators, genes, vectors and related transformed plants |
| 06/10/2009 | EP1711593B1 Process for the preparation of l-amino acids using strains of the family enterobacteriaceae |
| 06/10/2009 | EP1685254B1 Oncolytic herpes simplex virus encoding a heterologous nitroreductase |
| 06/10/2009 | EP1573016A4 Gene reporter assay, kit, and cells for determining the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein |
| 06/10/2009 | EP1487499B1 Contrast agents for magnetic resonance imaging and methods related thereto |
| 06/10/2009 | EP1409667B2 Process for preparing variant polynucleotides |
| 06/10/2009 | EP1362109B1 Recombinant oligomeric protein complexes with enhanced immunogenic potential |
| 06/10/2009 | EP1352070B1 A fibrin/fibrinogen-binding conjugate |
| 06/10/2009 | EP1294899B1 16836, a human phospholipase c family member and uses thereof |
| 06/10/2009 | EP1242626B1 Detection of nucleic acids |